Sylvia Cheung

Chief Financial Officer at Oculis

Ms. Cheung has 20 years of financial and general management experience at emerging growth life science companies. She joins Oculis from the NASDAQ-listed company Anika Therapeutics, Inc. where she was CFO from 2013 to 2020. During her tenure, she played a vital role in redefining and executing the company’s mission, vision and long-range financial-operational targets; supported and enabled U.S. launches of key therapeutics products; and executed on three strategic acquisitions. Prior to Anika, Ms. Cheung held a series of financial management positions of increasing responsibility at Transkaryotic Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Ms. Cheung began her career in the technology audit practice at PricewaterhouseCoopers. She holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as CPA in Massachusetts.

Location

Lexington, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Oculis

1 followers

Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back-and front-of-the-eye in order to improve the sight and the lives of patients worldwide.


Industries

Employees

11-50

Links